Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
Department of Hematology, Shengli Oilfield Central Hospital, Dongying, China.
Platelets. 2020;31(1):55-61. doi: 10.1080/09537104.2019.1572875. Epub 2019 Feb 11.
Immune thrombocytopenia (ITP) is an autoimmune disease with a mild to severe risk of bleeding complications. First line treatment includes corticosteroids, immunoglobulins, or other. In this large cohort study, first-line strategies for treatment-naive adult primary ITP was studied in a real-world setting. Records from all adult ITP patients who received first-line treatment between January 2010 and December 2017 at Qilu Hospital were reviewed retrospectively ( = 699). During the study period, 271 patients were treated with high-dose dexamethasone (HDD) and 289 patients were treated with conventional prednisone (alone or in combination with other drugs). Initial responses were similar for the two groups (88.56% vs. 86.51%, = 0.462), but patients in the HDD group responded earlier than the prednisone group (3 days vs. 5 days, 0.001). The sustained response (SR) at 6 months was lower in the HDD group than in the prednisone group (35.4% vs. 47.1%, = 0.040). However, the SR at 12 months and at the end of our follow-up were not significantly different between the groups. Overall duration of response (DOR) in the prednisone group was longer than in the HDD group throughout the follow-up period (0.007). However, the incidence of SR and overall DOR were not significantly different between the HDD group and the prednisone 3 months group (prednisone terminated within 3 months). The presence of anti-GPIb-IX autoantibodies was a predictive factor for a poor initial response to corticosteroids therapy ( < 0.05). However, neither of the two antiplatelet autoantibodies were correlated with the opportunity to achieve SR and overall DOR in both groups throughout the follow-up period ( > 0.05). Adverse events were more frequent and long-lasting in the prednisone group. Our study showed that HDD provided an effective and more rapid response as initial treatment of ITP, with comparable long-term prognosis and better tolerance when compared with conventional PDN (less than 3 months) in the real-world setting.
免疫性血小板减少症 (ITP) 是一种具有轻度至重度出血并发症风险的自身免疫性疾病。一线治疗包括皮质类固醇、免疫球蛋白或其他药物。在这项大型队列研究中,研究了在真实环境中治疗初治成人原发性 ITP 的一线治疗策略。回顾性分析了 2010 年 1 月至 2017 年 12 月期间在齐鲁医院接受一线治疗的所有成年 ITP 患者的记录(= 699)。在研究期间,271 例患者接受高剂量地塞米松(HDD)治疗,289 例患者接受常规泼尼松(单独或联合其他药物)治疗。两组患者的初始反应相似(88.56% vs. 86.51%,= 0.462),但 HDD 组患者的反应时间早于泼尼松组(3 天 vs. 5 天,0.001)。HDD 组患者的 6 个月持续反应(SR)低于泼尼松组(35.4% vs. 47.1%,= 0.040)。然而,两组患者在 12 个月和随访结束时的 SR 没有显著差异。在整个随访期间,泼尼松组的反应持续时间(DOR)长于 HDD 组(0.007)。然而,HDD 组和泼尼松 3 个月组(泼尼松在 3 个月内停药)的 SR 和总 DOR 发生率没有显著差异。抗 GPIb-IX 自身抗体的存在是皮质类固醇治疗初始反应不良的预测因素(<0.05)。然而,在整个随访期间,两组患者的两种抗血小板自身抗体均与 SR 和总 DOR 的机会无关(>0.05)。泼尼松组的不良事件更频繁且持续时间更长。我们的研究表明,在真实环境中,与常规 PDN(<3 个月)相比,HDD 作为 ITP 的初始治疗提供了更有效和更快的反应,具有可比的长期预后和更好的耐受性。